A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma

Morie Gertz, J. P. Garton, P. R. Greipp, Thomas Elmer Witzig, R. A. Kyle

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A single-arm, phase II prospective clinical trial was done in a tertiary care setting to determine the efficacy of high dose methylprednisolone in the treatment of patients with refractory or relapsed multiple myeloma. Twenty patients who had failed at least one chemotherapeutic regimen received methylprednisolone (2 g) intravenously three times weekly for 8 weeks. After 8 weeks, responders were placed on a maintenance phase of 2 g intravenously weekly with an 8-week reinduction at the time of relapse. Five patients died within the first month of therapy. There were two complete responses, two objective responses and three minor responses. The median survival for all 20 patients was 2.2 months. Median survival for the seven responders was 19 months, with a relapse-free survival of 15 months. Five patients survived at least 16 months. High-dose methylprednisolone is an easily administered, relatively nontoxic, and effective therapy in a subset of patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)2115-2118
Number of pages4
JournalLeukemia
Volume9
Issue number12
StatePublished - Dec 1995

Fingerprint

Methylprednisolone
Multiple Myeloma
Survival
Recurrence
Phase II Clinical Trials
Tertiary Healthcare
Therapeutics
Maintenance

Keywords

  • Corticosteroids
  • Methylprednisolone
  • Multiple myeloma
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. / Gertz, Morie; Garton, J. P.; Greipp, P. R.; Witzig, Thomas Elmer; Kyle, R. A.

In: Leukemia, Vol. 9, No. 12, 12.1995, p. 2115-2118.

Research output: Contribution to journalArticle

Gertz, Morie ; Garton, J. P. ; Greipp, P. R. ; Witzig, Thomas Elmer ; Kyle, R. A. / A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. In: Leukemia. 1995 ; Vol. 9, No. 12. pp. 2115-2118.
@article{b010cae5d5f64a6b98be5d6061fd3333,
title = "A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma",
abstract = "A single-arm, phase II prospective clinical trial was done in a tertiary care setting to determine the efficacy of high dose methylprednisolone in the treatment of patients with refractory or relapsed multiple myeloma. Twenty patients who had failed at least one chemotherapeutic regimen received methylprednisolone (2 g) intravenously three times weekly for 8 weeks. After 8 weeks, responders were placed on a maintenance phase of 2 g intravenously weekly with an 8-week reinduction at the time of relapse. Five patients died within the first month of therapy. There were two complete responses, two objective responses and three minor responses. The median survival for all 20 patients was 2.2 months. Median survival for the seven responders was 19 months, with a relapse-free survival of 15 months. Five patients survived at least 16 months. High-dose methylprednisolone is an easily administered, relatively nontoxic, and effective therapy in a subset of patients with multiple myeloma.",
keywords = "Corticosteroids, Methylprednisolone, Multiple myeloma, Treatment",
author = "Morie Gertz and Garton, {J. P.} and Greipp, {P. R.} and Witzig, {Thomas Elmer} and Kyle, {R. A.}",
year = "1995",
month = "12",
language = "English (US)",
volume = "9",
pages = "2115--2118",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma

AU - Gertz, Morie

AU - Garton, J. P.

AU - Greipp, P. R.

AU - Witzig, Thomas Elmer

AU - Kyle, R. A.

PY - 1995/12

Y1 - 1995/12

N2 - A single-arm, phase II prospective clinical trial was done in a tertiary care setting to determine the efficacy of high dose methylprednisolone in the treatment of patients with refractory or relapsed multiple myeloma. Twenty patients who had failed at least one chemotherapeutic regimen received methylprednisolone (2 g) intravenously three times weekly for 8 weeks. After 8 weeks, responders were placed on a maintenance phase of 2 g intravenously weekly with an 8-week reinduction at the time of relapse. Five patients died within the first month of therapy. There were two complete responses, two objective responses and three minor responses. The median survival for all 20 patients was 2.2 months. Median survival for the seven responders was 19 months, with a relapse-free survival of 15 months. Five patients survived at least 16 months. High-dose methylprednisolone is an easily administered, relatively nontoxic, and effective therapy in a subset of patients with multiple myeloma.

AB - A single-arm, phase II prospective clinical trial was done in a tertiary care setting to determine the efficacy of high dose methylprednisolone in the treatment of patients with refractory or relapsed multiple myeloma. Twenty patients who had failed at least one chemotherapeutic regimen received methylprednisolone (2 g) intravenously three times weekly for 8 weeks. After 8 weeks, responders were placed on a maintenance phase of 2 g intravenously weekly with an 8-week reinduction at the time of relapse. Five patients died within the first month of therapy. There were two complete responses, two objective responses and three minor responses. The median survival for all 20 patients was 2.2 months. Median survival for the seven responders was 19 months, with a relapse-free survival of 15 months. Five patients survived at least 16 months. High-dose methylprednisolone is an easily administered, relatively nontoxic, and effective therapy in a subset of patients with multiple myeloma.

KW - Corticosteroids

KW - Methylprednisolone

KW - Multiple myeloma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0029582856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029582856&partnerID=8YFLogxK

M3 - Article

C2 - 8609725

AN - SCOPUS:0029582856

VL - 9

SP - 2115

EP - 2118

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -